HLA-B*5801 Testing to Prevent Allopurinol Hypersensitivity Syndrome-Reference-Cited by-同舟云学术

HLA-B*5801 Testing to Prevent Allopurinol Hypersensitivity Syndrome

Published:2018-09-01 Issue:9 Volume:178 Page:1260
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Quach Cuong¹,Galen Benjamin T.²

Affiliation:

1. Albert Einstein College of Medicine and Montefiore Medical Center, Department of Internal Medicine, Residency Training Program, Bronx, New York

2. Albert Einstein College of Medicine and Montefiore Medical Center, Department of Internal Medicine, Division of Hospital Medicine, Bronx, New York

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Reference5 articles.

1. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.;Khanna;Arthritis Care Res (Hoboken),2012

2. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.;Hung;Proc Natl Acad Sci U S A,2005

3. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States.;Jutkowitz;Semin Arthritis Rheum,2017

4. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.;Ko;BMJ,2015

5. Centers for Medicare and Medicaid Services. Clinical Laboratory Fee Schedule. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Clinical-Laboratory-Fee-Schedule-Files-Items/18CLAB.html. Accessed May 29, 2018.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Cardiovascular Risks of Febuxostat and Allopurinol in Patients with Diabetes Mellitus and Chronic Kidney Disease;Medical Science Monitor;2024-05-01

2. Biomass Synthesis of Carbon Dots;Green Development of Photoluminescent Carbon Dots;2023-11-17

3. Syndrome d’hypersensibilité à l’allopurinol;Canadian Medical Association Journal;2023-07-16

4. Allopurinol hypersensitivity syndrome;Canadian Medical Association Journal;2023-04-02

5. Evaluation of pharmacogenomic evidence for drugs related to ADME genes in CPIC database;Drug Metabolism and Personalized Therapy;2022-10-19